07.31.25 -- Relationship Equity With CDMOs Is Real, Take It From A Packaging Pro

A successful large-scale public health emergency response requires adaptable manufacturing capabilities, an experienced workforce, and effective private-public partnerships.

A properly executed virtual audit facilitates thorough qualification, condenses production timelines, enhances relationship-building, and provides early insight into a CDMO’s capability and expertise.

Gain valuable insights into advanced methods and analysis techniques for high-order structure, physiochemical characterization, cell-based, biochemical assays, and more.

Antibody-drug conjugates (ADCs) are on the rise. Supply chains to serve ADC developers can be complicated, and spread out. Reza Oliyai has some key interpretations of how these therapies can string together optimal - and at times far-reaching - supply chains.

Observe how we helped a Southeast U.S. manufacturer by transitioning key staff, reducing costs, and fully managing a compliant GMP QC lab program.

Partner with a CDMO that understands the unique challenges of emerging biopharma, providing expert guidance in formulation development, manufacturing, and regulatory navigation.

Explore innovative solutions to overcome the limitations of traditional batch chromatography, improving efficiency, reducing costs, and optimizing production for complex biologics like monoclonal antibodies.

By partnering with a trusted company that offers expertise in navigating the challenges of scale up, drug developers can have confidence in their ability to successfully bring their products to market.

Examine the key findings of a new wearable injector clinical trial, including its positive impact on patient experience and the broader benefits of wearable injectors for chronic disease management.

Consider actionable strategies that can lead to higher success rates and smarter resource investment, paving the way for a successful path to IND submissions and commercialization.

Examine a human-relevant model that outperforms frozen mucosa and aligns better with clinical outcomes for opioid formulations.

Learn about antibody production and purification, as well as antibody humanization, while exploring an integrated pipeline that enables the direct application of machine learning tools.

As pressure to accelerate timelines mounts, finding a CDMO committed to optimizing processes with innovative technologies is key for adding efficiency while maintaining quality standards.

Streamline your journey to market by using the same proven CHO cell line and vectors from discovery through to commercial production.

Witness how proven sterile fill-finish expertise, high-potency capabilities, and customizable cleanrooms can support your product from development to commercialization.